Swiss Soliris® aHUS Reimbursement Registry SSaRR: Observational registry of patients suffering from atypical Hemolytic Uremic Syndrome (aHUS) who are treated with Soliris® (Eculizumab)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/40071
• EU PAS number:
  EUPAS37301
• Study ID:
  40071
• Official title and acronym:
  Swiss Soliris® aHUS Reimbursement Registry SSaRR: Observational registry of patients suffering from atypical Hemolytic Uremic Syndrome (aHUS) who are treated with Soliris® (Eculizumab)
• DARWIN EU® study:
  No
• Study countries:
  Switzerland
• Study status:
  Ongoing

Research institutions and networks

Institutions

Hôpitaux Universitaires de Genève (HUG)

Inselspital

Hôpitaux Universitaires de Genève Switzerland, Centre Hospitalier Universitaire Vaudois Switzerland, Inselspital Bern Switzerland, Kantonsspital Frauenfeld Switzerland, Kantonsspital Luzern Switzerland, Universitätsspital Basel Switzerland, Kantonsspital Aarau Switzerland, Universitätsspital Zürich Switzerland, Kantonsspital Chur & Kantonsspital St. Gallen Switzerland, Ente Ospedaliero Cantonale Bellinzona Switzerland

Study timelines

Date when funding contract was signed

Actual: 06/11/2018

Study start date

Actual: 06/11/2018

Data analysis start date

Actual: 17/09/2019

Date of final study report

Planned: 31/10/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Alexion Pharma GmbH

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable